Rhaeos, Inc.

Rhaeos, Inc. is a venture-backed, clinical-stage medical device company based in Evanston, Illinois, in the United States. The company is developing FlowSense, a patent-protected platform technology consisting of a non-invasive, wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. Rhaeos describes FlowSense as capable of assessing hydrocephalus shunt flow in minutes. The company's initial clinical target is hydrocephalus, a life-threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). The gold-standard treatment for hydrocephalus is an implantable shunt, but these shunts often fail, leading to repeated emergency department visits and repeat surgeries. According to Rhaeos, there is no technology available today that can easily assess CSF flow in shunts wirelessly, at the bedside, and without capital equipment — a gap the company aims to fill with FlowSense. Rhaeos frames the clinical and economic burden of hydrocephalus in the United States as substantial: it cites approximately 1 million Americans living with hydrocephalus, a 70% emergency department discharge rate among pediatric patients discharged after visiting the ED for symptoms of shunt malfunction, a 16% readmission rate within 30 days after shunt surgery, and more than $2 billion in annual impact to the US healthcare system from treating hydrocephalus. The company positions its technology for use across sites of care, including in-hospital, ambulatory, and in-home settings. Rhaeos engages with the hydrocephalus community and clinical community through events such as the Chicago WALK to End Hydrocephalus and the Joint Pediatric Section Annual Meeting. As a clinical-stage company, Rhaeos is focused on developing and validating its FlowSense platform rather than on commercial-scale product sales.

Rhaeos, Inc. is a venture-backed, clinical-stage medical device company based in Evanston, Illinois, in the United States. The company is developing FlowSense, which it describes as a patent-protected platform technology: a non-invasive, wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. The company's initial clinical focus is hydrocephalus, a life-threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts are the gold-standard treatment for hydrocephalus, but according to Rhaeos they often fail, leading to multiple trips to the emergency room and repeat surgeries. Rhaeos states that there is no technology available today that can easily assess CSF flow in shunts wirelessly, at the bedside, and without capital equipment — a gap the company intends FlowSense to address. The company says FlowSense can assess hydrocephalus shunt flow in minutes. Rhaeos highlights the scale of the hydrocephalus burden in the United States, citing approximately 1 million Americans living with hydrocephalus, a 70% emergency department discharge rate among pediatric patients discharged after visiting the ED for symptoms of shunt malfunction, a 16% readmission rate within 30 days after shunt surgery, and more than $2 billion in annual impact to the US healthcare system from treating hydrocephalus. The company positions FlowSense for use across sites of care, including in-hospital, ambulatory, and in-home settings. Rhaeos also engages with the hydrocephalus and clinical communities through events, including the Chicago WALK to End Hydrocephalus and the Joint Pediatric Section Annual Meeting. As a clinical-stage company, Rhaeos remains focused on developing and validating its FlowSense platform.

Clinical-stage medical device company developing a non-invasive, wireless, wearable platform for assessing and monitoring subdermal fluid flow, initially for hydrocephalus shunt flow assessment at the bedside and across in-hospital, ambulatory, and in-home sites of care.

• FlowSense

  A patent-protected platform technology: a non-invasive, wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. Rhaeos says FlowSense assesses hydrocephalus shunt flow in minutes.

1. 1Home - Rhaeosrhaeos.com
2. 2Company - Rhaeosrhaeos.com
3. 3Rhaeos, Inc. (United States) - Wikidatawikidata.org